...Unidentified 1 Data in the first half of 2026. So that's our, lead program where we can talk a lot more about that as we go through and including kind of the unmet need that these patients face, which is quite significant. And then, very briefly on the rest of the pipeline, we have AMX 35, which targets endopas reticulum stress and mitochondrial dysfunction. We just reported data in Wolfram syndrome, phase two data that showed benefit across all the measures that we were measuring in Wolfram syndrome, which is an ultra rare, kind of endocrine and neurodegenerative disease. We also have data coming in the 3rd quarter in progressive snuclear palsy, which we've been excited about. And tau lowering that we've seen with AX 35 and our view AX 35 is the only drug that both crosses the blood brain barrier and gets intracellular and reduces tau, and PSP is a tauopathy. So that's where that kind of makes a lot of sense. And then finally we've started recruiting with AmX 114, our anti-sensoganucleotide...
